Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins
{{output}}
Introduction: The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1, are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor venetoclax in 2016 validated the strategy of target... ...
